New drug combo shows promise in slowing esophageal cancer

NCT ID NCT03957590

Completed Disease control Sponsor: BeiGene Source: ClinicalTrials.gov ↗

First seen Apr 18, 2026 · Last updated May 13, 2026 · Updated 4 times

Summary

This study tested whether adding the drug tislelizumab to standard chemoradiotherapy helps people with localized esophageal squamous cell carcinoma. 370 participants received either tislelizumab or a placebo alongside their cancer treatment. The main goal was to see if the drug combination could delay cancer growth or improve survival.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Affiliated Hospital of Jiangsu University

Zhenjiang, Jiangsu, 212001, China
Beijing Cancer Hospital

Beijing, Beijing Municipality, 100142, China
Cancer Hospital Chinese Academy of Medical Sciences

Beijing, Beijing Municipality, 100021, China
Changzhou Tumor(Fourth Peoples)Hospital

Changzhou, Jiangsu, 213000, China
Chongqing Cancer Hospital

Chongqing, Chongqing Municipality, 400030, China
Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, 200000, China
Fujian Cancer Hospital

Fuzhou, Fujian, 350014, China
Hangzhou Cancer Hospital

Hangzhou, Zhejiang, 310002, China
Harbin Medical University Cancer Hospital

Harbin, Heilongjiang, 150000, China
Henan Cancer Hospital

Zhengzhou, Henan, 450000, China
Heping Hospital Affiliated to Changzhi Medical College

Changzhi, Shanxi, 046000, China
Hubei Cancer Hospital

Wuhan, Hubei, 430079, China
Hunan Cancer Hospital

Changsha, Hunan, 410013, China
Inner Mongolia Autonomous Region Cancer Hospital

Hohhot, Inner Mongolia, 010028, China
Jiangsu Province Hospital

Nanjing, Jiangsu, 210029, China
Jieyang Peoples Hospital (Jieyang Affiliated Hospital, Sun Yat Sen University )

Jieyang, Guangdong, 522000, China
Jinhua Municipal Central Hospital

Jinhua, Zhejiang, 321000, China
Liaoning Cancer Hospital and Institute

Shenyang, Liaoning, 110042, China
Northern Jiangsu Peoples Hospital

Yangzhou, Jiangsu, 225001, China
Shandong Cancer Hospital

Jinan, Shandong, 250117, China
Sichuan Cancer Hospital and Institute

Chengdu, Sichuan, 610041, China
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine

Hangzhou, Zhejiang, 310016, China
The Affiliated Hospital of Xuzhou Medical University

Xuzhou, Jiangsu, 221000, China
The First Affiliated Hospital of Xiamen University

Xiamen, Fujian, 361003, China
The First Affiliated Hospital of Xian Jiaotong University

Xi'an, Shaanxi, 710061, China
The First Affiliated Hospital of Xinxiang Medical University

Xinxiang, Henan, 453100, China
The First Affiliated Hospital, Zhejiang University School of Medicine

Hangzhou, Zhejiang, 310003, China
The First Affiliated Hospitalschool of Clinical Medicine of Guangdong Pharmaceutical University

Guangzhou, Guangdong, 510000, China
The First Peoples Hospital of Lianyungang

Lianyungang, Jiangsu, 222002, China
Tianjin Medical University Cancer Institute and Hospital

Tianjin, Tianjin Municipality, 300060, China
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, 430022, China
Weifang Peoples Hospital

Weifang, Shandong, 261000, China
West China Hospital, Sichuan University

Chengdu, Sichuan, 610041, China

Conditions

Explore the condition pages connected to this study.

ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)